Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00337220 · ClinicalTrials.gov registry record
Urine Testing to Detect Kidney Transplant Rejection
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 492
- Enrollment target
NCT00337220: Completed study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00337220 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 492 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00337220 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 492 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if analysis of urine samples for specific markers can predict transplant rejection in people who have received kidney transplants.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 492 participants |
| Start Date | 2006-06 |
| Est. Completion | 2010-12 |
What the finished NCT00337220 record still lists
NCT00337220 is an observational study that tracks outcomes without assigning an intervention. The registered 492 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00337220 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00337220 about?
NCT00337220 is a clinical study titled "Urine Testing to Detect Kidney Transplant Rejection". The purpose of this study is to determine if analysis of urine samples for specific markers can predict transplant rejection in people who have received kidney transplants.
What is the current status of trial NCT00337220?
This trial is currently completed. The enrollment target is 492 participants. The study started on 2006-06. Estimated completion is 2010-12.
Who is sponsoring clinical trial NCT00337220?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05861973 · 492 participants · NA
SMARTer Weight Loss Management
- NCT05908331 · 492 participants · NA
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
- NCT06152575 · 492 participants · Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- NCT06953089 · 492 participants · Phase 2
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia